New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT03179904
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new drug called TVB-2640 (denifanstat) combined with trastuzumab and either chemotherapy (paclitaxel) or hormone therapy in 17 people with HER2+ metastatic breast cancer that no longer responds to trastuzumab. TVB-2640 blocks an enzyme cancer cells need to grow, while trastuzumab targets HER2 receptors. The goal is to see if this combination can shrink tumors and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denifanstat (TVB-2640), a FASN inhibitor, combined with trastuzumab and either paclitaxel or endocrine therapy
What this could lead to
If successful, this could offer a new treatment option for people with HER2+ metastatic breast cancer whose cancer has stopped responding to standard trastuzumab-based therapy.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors in many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States